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Abstract 
 
Burmeister, Rachel, M.S., May 2019            Toxicology 
 
Prevention of Crystalline Silica-Induced Inflammation by the Anti-Malarial Hydroxychloroquine 
 
Chairperson:  Andrij Holian 
 
 
Exposure to inhaled crystalline silica (cSiO2) is common in occupations where there is cutting, 
milling, or grinding of cSiO2 containing material. The Occupational Safety and Health 
Administration estimates that over 2 million workers may be exposed to inhaled cSiO2 in the 
United States. Inhalation of cSiO2 causes acute and chronic inflammation and may lead pulmonary 
diseases such as silicosis, as well as an increased risk of developing autoimmune diseases. 
Unfortunately, treatment of cSiO2-induced lung diseases is limited and primarily focused on 
supportive care.  
 
Inflammation caused by cSiO2 begins when, cSiO2 particles are phagocytized by alveolar 
macrophages. Interaction between the particle and lysosomal membrane results in damage to the 
phagolysosomal membrane; a state known as lysosomal membrane permeability (LMP). Leakage 
of lysosomal contents into the cytoplasm induces NLRP3 inflammasome activation leading to cell 
death and systemic inflammation. There are currently no pharmaceutical treatments that are 
directed at this mechanism of disease. Many existing pharmaceuticals become sequestered in the 
lysosome through an ion-trapping mechanism, and our laboratory aims to determine if these 
pharmaceuticals are capable of blocking permeabilization of the lysosomal membrane. Previously, 
our laboratory has shown that the tricyclic antidepressant, imipramine, blocks inflammatory 
cytokine production and toxicity in alveolar macrophages after exposure to cSiO2. The objective 
of this research is to determine whether another pharmaceutical, hydroxychloroquine, prevents 
cSiO2-induced toxicity by blocking LMP in alveolar macrophages. The ability to target the 
mechanism responsible for initiating particle-induced inflammation may lead to potential 
treatments and prevention strategies for people exposed to cSiO2. 
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Chapter 1: Background and Significance 
 1.1 Silica Exposure 
 
Exposure to inhaled crystalline silica particles (cSiO2) remains a significant occupational health 
concern. The Occupational Safety and Health Administration (OSHA) estimates that over 2 
million workers may be chronically exposed to inhaled cSiO2 in the United States alone (Bang et 
al., 2015). Lung disease caused by cSiO2 inhalation was recognized as an occupational hazard as 
far back as 1690 when Hippocrates observed that miners often developed difficulty breathing 
(Greenberg, Waksman, & Curtis, 2007). However, it is now known that cSiO2 exposure is 
associated with both pulmonary and systemic disease including pulmonary fibrosis, silicosis, 
chronic inflammation, and autoimmune diseases (Pollard, 2016). 
 
Materials containing cSiO2 are used for purposes ranging from building materials to electronic 
components (IARC, 2012). Exposure is most common in occupations such as mining, 
construction, and manufacturing where cSiO2 containing materials are mechanically disturbed 
creating inhalable aerosolized particles less than 10 µm in size (Leung, Yu, & Chen, 2012; Pollard, 
2016). While the use of control measures, including dust control and wet-milling practices, have 
been successful at reducing the cases of silicosis in the United States and other developed 
countries, overexposures happen regularly and low level exposures over long time-frames are 
common (Bang et al., 2015; Castranova & Vallyathan, 2000). Modern technologies are also 
creating new opportunities for exposure. Silica nanoparticles have become the most widely used 
nanotechnology and are being used extensively for biomedical purposes (J. Wang et al., 2017). In 
the developing world, cSiO2 exposure is more common due to a lack of regulation and use of 
personal protection equipment. Additionally, the demographics of cSiO2 exposed populations in 
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developing countries may be markedly different from developed nations. In the United States the 
majority of people employed in trades where cSiO2 exposure is likely have historically been men, 
and between 2001-2010 over 95% of silicosis cases in the United States were male. In developing 
countries women and children make up a significant portion of cSiO2 exposures due to the 
increased likelihood of these individuals being employed in unskilled work (Brass et al., 2010; 
Sharma, 2008; Tiwari, Saha, & Parikh, 2009).  
 
Pulmonary morbidities associated with the deposition of cSiO2 in the lungs include bronchitis, 
silicosis, chronic obstructive pulmonary disease, increased risk of tuberculosis infections, and 
cancer. Additionally, cSiO2 exposure is associated with development of systemic diseases 
including rheumatoid arthritis, scleroderma, systemic lupus erythematosus, and chronic renal 
disease (Leung et al., 2012; Pollard, 2016). This research focuses on the mechanisms following 
cSiO2 exposure that lead to silicosis. Silicosis is a fibrotic disease characterized by pulmonary 
edema, chronic interstitial inflammation, and the development of silicotic nodules (Kawasaki, 
2015). Silicosis is classified into several subtypes determined by the amount of cSiO2 inhaled and 
length of exposure period. Acute silicosis, also called silicoproteinosis, occurs after exposure to 
high levels of cSiO2 for a short period of time. During acute silicosis the alveolar spaces become 
filled with lipid and protein rich fluid and extensive neutrophilic infiltration occurs. Patients 
experience severe symptoms due to decreased gas exchange capabilities and respiratory failure 
(Castranova & Vallyathan, 2000). Chronic silicosis develops after 15-20 years of low to moderate 
cSiO2 exposure and is the most commonly seen form of silicosis due to occupational exposures. 
An accelerated form of chronic silicosis can occur after 5-10 years of higher exposure levels 
(Pollard, 2016).   
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After inhalation, cSiO2 particles small enough to enter deep into the lung reach the alveolar spaces; 
however, cellular mechanisms for clearing debris from the alveolar spaces are ineffective at 
removing cSiO2 particles. When the resident alveolar macrophages (AM) attempt to phagocytize 
and clear the particles, the cSiO2 causes caspase-1 dependent pyroptosis of the AM (Bergsbaken, 
Fink, & Cookson, 2009). This propagates a chronic inflammatory response as subsequent AM 
ingest the particles and continue a cycle of cell death. The damaged cells release damage-
associated molecular patterns (DAMPs) and inflammatory cytokines such as TNF-α, IL-1b, and 
IL-6 recruiting other inflammatory cells, primarily other macrophages and polymorphonuclear 
neutrophils, and stimulating fibrogenic processes (Beamer & Holian, 2007; Kawasaki, 2015; 
Pollard, 2016; Rimal, Greenberg, & Rom, 2005). Fibroblasts surround the cSiO2 particles with 
collagen creating fibrotic nodules which increase in size as disease progresses. The nodules can 
become necrotic and massive fibrosis develops throughout the lungs. The resulting damage can be 
severe and compromise pulmonary function (Rimal et al., 2005). 
 
1.2 The NLRP3 Inflammasome and Lysosomal Membrane Permeability  
 
Inflammation induced by cSiO2 is directed by the NLRP3 inflammasome which drives the 
production of the inflammatory cytokines IL-1b and IL-18 (Jo, Kim, Shin, & Sasakawa, 2016; 
Sayan & Mossman, 2016). Two signals are required for the induction of the NLRP3 inflammasome 
(Fig. 1). The first signal is a priming signal which upregulates expression of the NLRP3 
components. It is dependent on activation of the NF-kB pathway through TLR signaling due to 
various pathogen-associated molecular patterns (PAMPs) or damage-associated molecular 
patterns (DAMPs) (Biswas, Hamilton, & Holian, 2014; Sayan & Mossman, 2016). The 
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translocation of NF-kB to the nucleus also increases transcription of pro-IL-1b and pro-IL-18. A 
second signal induces the assembly of the NLRP3 inflammasome into the multi-protein complex 
containing the apoptosis-associated speck-like protein (ASC) which binds to procaspase-1. 
Procaspase-1 is cleaved into an active form and in turn cleaves pro-IL-1b and pro-IL-18 into their 
mature, secreted forms  (Hornung et al., 2008). Together, the first signal and the second signal 
induce an inflammatory cascade and ultimately cell death (Bunderson-Schelvan et al., 2016). 
 
There are several mechanisms proposed to initiate the second signal. These include potassium 
efflux, mitochondrial damage, reactive oxygen species production, and lysosomal injury; however, 
the primary mechanism of cSiO2-produced NLRP3 induction is thought to be lysosomal injury  (Jo 
et al., 2016). When cSiO2 particles are phagocytized by AM, they interact with the interior of the 
phagolysosomal membrane and cause disruption to the membrane.  This is referred to as lysosomal 
membrane permeability (LMP) (Bunderson-Schelvan et al., 2016; Serrano-Puebla & Boya, 2016). 
The compromised lysosomal membrane allows the acidic hydrolases, including cathepsin B, 
normally contained by the lysosome to leak into the cytosol (P Boya & Kroemer, 2008). There are 
currently no pharmaceuticals that target a molecular mechanism of cSiO2 toxicity to reverse or 
prevent silicosis; however, targeting the lysosome in order to block LMP could be a promising 
way to diminish cSiO2 toxicity (Biswas et al., 2017).  
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Figure 1: Proposed model of LMP 
 
Model of the inflammatory cascade following particle-induced lysosomal membrane permeability. 
(Bunderson-Schelvan et al., 2016) 
 
1.3 Cationic Amphiphilic Drugs 
 
Many existing pharmaceuticals are known to interact with and become sequestered in the 
lysosome. This primarily occurs in a class of drugs known as cationic amphiphilic drugs (CAD). 
CAD tend to be weak bases that easily diffuse through membranes in their unprotonated state. 
Once they have diffused into the lysosome, they become protonated in the acidic environment 
subsequently preventing them from diffusing out of the lysosome. This ion-trapping mechanism 
results in a high concentration of drug stored within the lysosome (Villamil Giraldo et al., 2014). 
While this is considered an off-target effect for many drugs, this action may provide an opportunity 
to prevent particle-induced damage. Previously, our laboratory has shown that one CAD, 
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imipramine (IMP), can reduce pulmonary inflammation after exposure to cSiO2 both in vivo and 
in vitro (Biswas et al., 2017). IMP is a tricyclic antidepressant that has been shown to have some 
protective effects against lung injury (Yang et al., 2010). Interestingly, another CAD, 
hydroxychloroquine (HCQ) is commonly used in the treatment of the autoimmune disease 
systemic lupus erythematosus (Fig. 2). Exposure to cSiO2 has been shown to contribute to the 
development of systemic lupus erythematosus; however there has been no research examining the 
effect of HCQ on cSiO2-induced toxicity.  
 
HCQ  has been extensively used to prevent malaria and as treatment for autoimmune diseases such 
as rheumatoid arthritis and systemic lupus erythematosus (Olsen, Schleich, & Karp, 2013). 
Recently HCQ has been investigated for use in diseases including endometriosis, cancer, 
cardiovascular disorders, diabetes, and infectious diseases (Ben-Zvi, Kivity, Langevitz, & 
Shoenfeld, 2012; D. Chen et al., 2018; Ruiz et al., 2016). There are many proposed mechanisms 
to explain how HCQ could be acting in such a diverse number of diseases. Some evidence has 
shown that HCQ can reduce inflammatory cytokine production by macrophages and alter 
macrophage phenotype (D. Chen et al., 2018). Other reports show changes in B and T cell signaling 
and inhibition of phospholipase A2 (Ben-Zvi et al., 2012). HCQ’s effect on cancer and 
endometriosis have been attributed to modulation of autophagy. Furthermore, in a murine model 
of endotoxic shock, Chen et al. showed that chloroquine can decrease activation of the NLRP3 
inflammasome and block production of IL-1b and IL-18 (D. Chen et al., 2018). However, no work 
has been done to examine whether HCQ accomplishes this by preventing destabilization of the 
lysosomal membrane nor if HCQ can prevent cSiO2-induced LMP. 
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Figure 2: Chemical structure of HCQ 
IUPAC name 2-[4-[(7-chloroquinolin-4-yl)amino]pentyl-ethylamino]ethanol 
 
1.4 Specific Aims 
 
The objective of this research was to determine if HCQ reduces cSiO2 toxicity in alveolar 
macrophages. There are currently no pharmaceuticals that target a molecular mechanism of cSiO2 
toxicity to reverse or prevent silicosis; however, targeting the lysosome in order to block LMP 
could be a promising way to diminish cSiO2 toxicity (Biswas et al., 2017). The objective of this 
research is to determine if HCQ has the ability to attenuate pulmonary cSiO2 toxicity. My 
hypothesis is that HCQ blocks LMP and decreases cSiO2-induced inflammation in alveolar 
macrophages. 
 
Specific Aim 1: Determine that cSiO2-induced toxicity is blocked by hydroxychloroquine in 
vitro.   
 
Hypothesis: LMP will be decreased in HCQ treated alveolar macrophages which are exposed to 
cSiO2 particles in vitro.  In vitro studies will be conducted in order to show that HCQ can prevent 
LMP after cSiO2 exposure. These studies will be conducted in bone marrow derived macrophages 
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(BMDM) from C57Bl/6 mice. LMP will be assessed through a digitonin assay measuring β-N-
acetylglucosaminidase release. Additionally, inflammasome activation, toxicity, and cytokine 
production will be measured.   
 
Methods: 
Toxicity Assays 
Using C57Bl/6 BMDM, I will show that HCQ blocks cSiO2-induced toxicity. BMDM will be 
exposed to various doses (0-50 µg/mL) of cSiO2. Toxicity will be analyzed with a common 
tetrazolium viability (MTS) assay (Promega, cat. G3580) and the lactate dehydrogenase assay 
(Promega, cat. G1780). NLRP3 inflammasome activation will be confirmed by assaying the 
release of IL-1b (R&D Systems, cat. DY201). 
Measures of LMP 
• In order to determine if HCQ can reduce LMP caused by cSiO2, LMP will be quantified 
through measurement of released a-N-acetylglucosaminidase after digitonin extraction 
based on Aits et al., 2015, as previously described by our laboratory (Aits, Jäättelä, & 
Nylandsted, 2015; Jessop, Hamilton, Rhoderick, Shaw, & Holian, 2016) 
• Alternative methods of assessing LMP using Lysotracker dyes will also be used. 
Phagocytosis 
To ensure that LMP is not being altered due to differences in phagocytosis after being 
treated with HCQ, the relative amount of particle phagocytized by macrophages will be 
assessed by measuring relative side-scatter by flow cytometry of untreated macrophages 
and those treated with HCQ.  
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Specific Aim 2: Establish that HCQ prophylactically reduces cSiO2-induced inflammation 
in a murine model of acute silicosis.  
 
Hypothesis: Mice treated with HCQ before cSiO2 treatment will show reduced toxicity after acute 
cSiO2 exposure.  C57Bl/6 mice will be treated with HCQ by oral gavage (to simulate normal 
pharmaceutical administration of HCQ by patients) for 7 days prior to oropharyngeal instillation 
of cSiO2. Twenty-four hours after cSiO2 exposure mice will be sacrificed. Inflammatory cytokines, 
cathepsin release, and toxicity will be assessed.  
 
Methods: Mice will be treated with HCQ (10 mg/kg) through oral gavage once per day for a 
duration of seven days. Mice will then be exposed to cSiO2 (0.25 mg or 1 mg) by oropharyngeal 
instillation and sacrificed 24 hours after exposure. Whole lung lavage fluid will be collected and 
assayed for cathepsin release as a measure of LMP. Lavage fluid will be assessed for protein, 
inflammatory cytokines (IL-1b, TNF-a, IL-6, IL-18, IL-33), cytotoxicity, and infiltration of 
immune cells.  
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Chapter 2: Methods 
2.1 Mice  
C57Bl/6 mice (Jackson Laboratories, Bar Harbor, ME) were housed in the University of 
Montana’s specific-pathogen-free Laboratory Animal Resources facility. The mouse room is 
maintained on a 12 hr light/dark cycle and mice were provided with mouse feed and deionized 
water ad libitum. Male and female mice between 8-16 weeks of age were used for the studies. 
Euthanasia was administered through intraperitoneal injection of a lethal dose of pentobarbital 
sodium (Euthasol, Virbac, Fort Worth, TX). The University of Montana Institutional Animal Care 
and Use Committee (Missoula, MT, USA) approved all procedures performed on the animals.  
2.2 Crystalline Silica 
Crystalline silica (Min-U-Sil-5, average particle size 1.5-2 µm in diameter) was obtained from 
Pennsylvania Sand Glass Corporation (Pittsburgh, PA), and acid washed in 1N HCl. The cSiO2 
was washed with sterile water four times and dried in an oven at 200°C. Before use, cSiO2 particles 
were suspended in PBS or dispersion media (for in vivo experiments) and sonicated for at least 2 
min (550 watts at 20 kHz) by a cup-horn sonicator in a circulating water bath (Misonix, Inc. 
Farmingdale, NY, USA). Dispersion media consisted of PBS containing 0.6 mg/ml mouse serum 
albumin and 0.01 mg/ml 1,2-dipalmitoyl-sn-glycero-3-phosphocholine.  
2.3 Isolation and Culture of Bone Marrow Derived Macrophages 
Bone Marrow Derived Macrophages (BMDM) were generated as described previously 
(Migliaccio, Buford, Jessop, & Holian, 2008; Pfau et al., 2004). C57Bl/6 mice were sacrificed and 
the hind legs were removed. Complete media (RPMI, 10% FBS, Penicillin/Streptomycin) was 
washed through the femur and tibia to collect the bone marrow cells. Cells were incubated in T75 
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flasks at a density of 3.0x107 overnight at 37°C for stromal elimination by adherence. The next 
day, nonadherent cells are transferred to a new flask at a density of 1.5x107 cells per flask.  
Macrophage colony stimulating factor (M-CSF) (20 ng/mL R&D Systems) was added and cells 
were spiked with M-CSF (10 ng/ml R&D Systems) every 3-4 days. BMDM were used on day 10.  
2.4 In Vitro Toxicity Assays 
BMDM were platted in a flat-bottom, tissue culture- treated 96-well plates at 1×105 cells/well in 
100 µL of RPMI complete media and incubated with lipopolysaccharides (LPS) (20 ng/mL) for 
inflammasome priming. Cells were treated with 25 µM of hydroxychloroquine sulfate (Sigma-
Aldrich cat. H0915-5MG), 25 µM imipramine hydrochloride (Sigma-Aldrich cat. 10899-5G), or 
100 nM bafilomycin (EnzoLife Sciences cat. BML-CM110-0100) for 30 minutes prior to addition 
of cSiO2. Cells were exposed to various doses (0-50 µg/mL) of cSiO2 and plates were incubated 
in a 37°C water-jacketed CO2 incubator (ThermoForma, Houston, TX) for 24 hours. Toxicity 
induced by cSiO2 was determined by two complementary assays, a lactate dehydrogenase assay 
(Promega, cat. G1780) and a common colorimetric tetrazolium viability (MTS) assay (Promega, 
cat. G3580), and read on a plate reader (Molecular Devices SpectraMax M4 colorimetric 
microplate reader). In order to avoid artifacts in the optical density values, the MTS reaction was 
transferred to a clean plate to separate it from the cell/particle mixture adhered to the plate bottom. 
Data were normalized to a percent relative to the no particle, no HCQ control cells. NLRP3 
inflammasome activation was assayed by measuring the release of IL-1β by using a commercially 
available ELISA kit (R&D Systems, cat. DY201).  
2.5 In Vivo Treatments 
C57Bl/6 mice were treated with either hydroxychloroquine (Hydroxychloroquine Sulfate, 
Calbiochem cat. 509272) reconstituted in PBS (10 mg HCQ/kg/per day) or vehicle (PBS) by oral 
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gavage once a day for seven days. After the seven days, mice were instilled with 1 mg or 0.25 mg 
of cSiO2 through oropharyngeal aspiration. Prior to gavage and instillation of cSiO2, mice were 
briefly anesthetized by isoflurane. For instillation, the sedated mouse is positioned vertically while 
50 µL of dispersion media with or without cSiO2 was dispensed with a pipette to the back of the 
throat. By holding the tongue to the side, the mouse could not swallow and, therefore, aspirated 
the volume into the lungs.  Mice were sacrificed 24 hours after cSiO2 exposure for analysis by 
collecting whole lung lavage fluid. The lungs and heart were removed from the chest cavity, and 
1 mL of cold PBS was washed in and out of the lungs four times in order to collect concentrated 
lung fluid. Samples were centrifuged at 400 x g for 5 minutes and the supernatant was saved for 
analysis. The lungs were lavaged with an additional 4 mL of PBS in order to collect the maximum 
number of cells.  Lavage cells were counted using a Coulter Z2 particle counter (Beckman Coulter, 
Brea, CA, USA) and resuspended in RPMI 1640 culture media supplemented with 10% fetal 
bovine serum, sodium pyruvate, and an antibiotic-antimycotic solution (Mediatech, Manassas, 
VA) for differential analysis or flow cytometry. Cells were stained for differential analysis with a 
Wright-Geimsa stain in a Hematek 2000 autostainer (Miles-Bayer-Siemens Diagnostics, 
Deerfield, IL, USA).  
2.6 In Vivo Lung Injury and Inflammation Assays  
Toxicity was measured in the lung lavage fluid by assaying for LDH as above. Cytokines from 
lung lavage fluid were measured by a multiplex immunoassay (MSD U-PLEX, Meso Scale 
Diagnostics, U-PLEX, cat K15069L-2) because of the sensitivity and small sample size used. 
Seven cytokines IFN-g, IL-1b, IL-6, IL-10, IL-13, IL-33, and TNF-a were included in the 7-plex 
plate used for this experiment. Protein in the lung lavage fluid was assayed by the Pierce BCA 
Protein Assay Kit (ThermoFisher Scientific cat. 23225) following manufacturers specifications. 
 13 
Extracellular cathepsin B release in the lavage fluid was analyzed as previously described by our 
laboratory (Sager et al., 2016). In a 96 well plate, 50 µL of whole lung lavage was combined with 
50 µL of a cathepsin B inhibitor (Calbiochem cat. 219385) or 50 µL PBS and incubated at room 
temperature for 15 min. Then the cathepsin substrate Z-LR-AMC (specific to cathepsin B, 
cathepsin L and cathepsin V; R&D systems cat. ES008) at 20 µL in PBS was added to 50 µL of 
whole lung lavage fluid in a total reaction volume of 150 µL. The assays were incubated at 37°C 
for 1 hour then fluorescence was measured using a plate reader at 380 nm excitation and 460 nm 
emission. The wells with the only the cathepsin substrate measured the total (cathepsin B, 
cathepsin L and cathepsin V) cathepsin activity in the lavage fluid while wells with the cathepsin 
B inhibitor measured the remaining cathepsin L and cathepsin V activity.  By subtracting the 
inhibitor wells from the total cathepsin well, the level of cathepsin B was calculated.  
2.7 Ex Vivo Culture for IL-1b Production 
 
Cells collected during the whole lung lavage of mice treated with 0.25 mg of cSiO2 in vivo were 
plated for ex vivo IL-1b culture. Lung lavage fluid was centrifuged and the supernatants saved for 
other analyses. Cells were resuspended in 250 µL of complete media, counted, and then 100 µL of 
cell suspension was plated in a 96 well plate. Cells were primed for inflammasome activity with 
LPS (20 ng/mL) and incubated for 24 hours at 37°C. After incubation, supernatants were collected 
and assayed with a commercial IL-1b kit (R&D Systems, cat. DY201). Data were normalized to 
IL-1b release per 1x105 AM using the total cell count and percent of macrophages in the whole 
lung lavage. 
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2.8 Flow Cytometry  
Flow cytometry was used to assess phagocytosis of cSiO2 particles and lysosomal uptake of 
LysoTracker dye both in BMDM and AM collected in the lung lavage of treated mice. 
Internalization of cSiO2 was determined by using a side-scatter technique previously described 
(Hamilton, Thakur, Mayfair, & Holian, 2006). BMDM or lung lavage cells were cultured or 
collected as described above. BMDM were treated with 25 µM HCQ for 30 minutes and then 
exposed to 50 µg/mL cSiO2 for 4 hours using 1.5 mL microfuge tubes and end over end tumbling 
(Lab Quaker Shaker, Thermo Forma). Lung lavage cells had no additional treatment of HCQ or 
cSiO2 after the in vivo exposures.  Both lung lavage cells and BMDM were treated with 
LysoTracker Red DND-99 (ex/em 577⁄590 nm, ThermoFisher Scientific cat. L7528) at 50 nM for 
30 min. The cells were centrifuged, resuspended in PAB, and transferred to filter-top flow 
cytometry tubes (BD Biosciences, San Jose, CA) for analysis. Phagocytosis and LysoTracker 
uptake data were expressed as mean fluorescent intensity. Cells were analyzed on a Life 
Technologies Attune NxT Acoustic Focusing Cytometer with the YL-1 585/16 nm laser.  
2.9 Lysosome Membrane Permeabilization Assay  
Lysosome membrane permeabilization (LMP) was assessed using methods modified from Aits et 
al. (Aits et al., 2015) and as described previously by our laboratory (Jessop, Hamilton, Rhoderick, 
Fletcher, & Holian, 2017). BMDM were plated in 24 well plates at a density of 2×105 cells per 
well. Cells were treated with or without HCQ (25 µM) and with or without cSiO2 (50 µg/mL). 
Cells were washed twice with PBS and placed on ice. BMDM were then incubated with 200 µL 
of cytosol extraction buffer, which consisted of 250 mM sucrose, 20 mM Hepes, 10 mM KCl, 1.5 
mM MgCl2, 1 mM EDTA, 1 mM EGTA, 0.5 mM pefabloc (Sigma-Aldrich cat. 76307-100mg), 
pH 7.5, and digitonin (15 µg/mL ) (Sigma-Aldrich cat. D141-100MG), for 15 min on ice with 
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rocking. The concentration of digitonin for optimal extraction of the cytosolic fraction was 
determined by titration. β-N-acetylglucosaminidase (NAG) activity was measured by adding 30 
µL cytosolic extract to 100 µL of NAG reaction buffer (0.2 M sodium citrate, pH 4.5 with 300 
µg/mL 4-methylumbelliferyl-2-acetamido-2-deoxy-β-D-glucopyranoside (Sigma-Aldrich cat. 
37067-30-4) and assessed on a plate reader (20 min; 45s intervals; 356 nm excitation; 444 nm 
emission). Extracted cytosolic LDH activity was measured as described above and used as a 
control to which the NAG activities were normalized.  
 
2.10 Statistical Analysis 
Depending on the data type, a parametric one or two-way analysis of variance (ANOVA), followed 
by post hoc mean comparison (Holms-Sidak etc.) was used throughout the research described. 
Statistical significance will be defined as a two-tailed probability of type I error at less than 5% (p 
< 0.05) unless otherwise stated. The minimum number of experimental replications was 3.  
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Chapter 3: Results 
 
3.1 HCQ decreases cSiO2 toxicity in vitro 
 
The ability of HCQ to decrease toxicity and cell death in vitro was assessed using C57Bl/6 BMDM. 
BMDM were primed for inflammasome activation with LPS (20 ng/mL) and then treated with 
either HCQ (25 µM), imipramine (IMP, 25 µM), or bafilomycin A1 (BAF, 100 nM) for 30 min 
prior to cSiO2 exposure. IMP and BAF were positive controls for blocking cSiO2-induced toxicity. 
Bafilomycin A1 (BAF) specifically inhibits vATPases to prevent lysosomal acidification, which 
previous studies have indicated is necessary for particle induced toxicity (Jessop et al., 2017). In 
biological systems small particles develop a protein shell called a protein corona. The protein 
corona is degraded in the acidic environment of the lysosomes which allows the particle to directly 
interact with the lipid membrane causing LMP. Preventing acidification is thought to prevent 
degradation of the protein corona and protect the lysosome from LMP (F. Wang et al., 2013).  
Imipramine, a tricyclic anti-depressant, was previously shown by our laboratory to block cSiO2-
induced toxicity; therefore, it was used as a comparison to HCQ (Biswas et al., 2017).  
 
Cells were exposed to 0, 50, or 100 µg/mL of cSiO2 and incubated for 24 hrs at 37° C. HCQ, IMP, 
and BAF were all found to block toxicity at both the 50 µg/mL and 100 µg/mL exposures of cSiO2 
as determined by the LDH assay and MTS assay (Fig. 3). No toxic effect from either HCQ or IMP 
alone was found in cells not exposed to cSiO2. Protective effects were more pronounced at the 50 
µg/mL cSiO2 exposure as there was significant cell death at the 100 µg/mL cSiO2 dose which could 
not be completely overcome by the HCQ, IMP, or BAF. Cell supernatants were assayed for IL-1β 
as a representative measure for NLRP3 inflammasome activation. IL-1β production was drastically 
decreased in exposed cells receiving HCQ, IMP, and BAF (Fig. 4).  
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Figure 3: HCQ decreases cSiO2-induced toxicity in BMDM.  
BMDM were treated with HCQ (25 µM), IMP (25 µM), or bafilomycin A1 (100 nM) and exposed 
to 0, 50, or 100 µg/mL of cSiO2. HCQ, IMP, and BAF caused statistically significant decrease in 
cSiO2 toxicity as determined by decreased LDH release and increased cell viability.  
(**** p < 0.0001, ** p < 0.01, * p < 0.05) n = 3-4 
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Figure 4: HCQ blocks the production of IL-1b in BMDM exposed to cSiO2.  
Cell supernatants were assayed for IL-1β as a representative measure for NLRP3 inflammasome 
activation. IL-1β production was blocked in exposed BMDM treated with HCQ (25 µM), IMP (25 
µM), or bafilomycin A1 (100 nM) at both 50 (** p < 0.01) and 100 µg/mL (**** p < 0.0001) cSiO2 
exposures. Symbols indicate significance between control and treated cells. n = 3-4 
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3.2 HCQ does not affect cSiO2 uptake in vitro 
 
In order to confirm that HCQ was not blocking cSiO2 toxicity by reducing phagocytosis of the 
cSiO2 particles, the amount of cSiO2 taken up by the BMDM was quantified by flow cytometry 
(Fig. 5).  BMDM which have taken up cSiO2 into their phagolysosomes have higher side-scatter 
(SSC) due to the deflection of laser light by the cSiO2 particles. BMDM exposed to cSiO2 (50 
µg/mL) with or without HCQ (25 µM) had significantly higher side scatter (****p < 0.0001) than 
BMDM not exposed to cSiO2. There was no difference between the SSC of control vs HCQ-treated 
cells nor cSiO2 vs HCQ + cSiO2 cells. This indicates that HCQ does not affect the ability of BMDM 
to take up cSiO2.  
 
Additionally, BMDM were also treated with LysoTracker Red DND-99 at 50 nM for 30 min (as 
per manufacturers recommendations) to assess the relative acidity of the lysosomes (Fig. 6). HCQ 
treatment caused a decrease in the amount of LysoTracker taken up by lysosomes. This finding 
suggests that HCQ is present in the lysosomes and may cause lysosomes to be less acidic. In turn, 
this may help protect the lysosomes from being permeabilized by cSiO2. Cells treated with HCQ 
or HCQ + cSiO2 had significantly less (*p < 0.05) LysoTracker uptake than control cells or cells 
exposed cSiO2 without HCQ treatment. Together, the in vitro results collected in these experiments 
are consistent with HCQ being able to reduce LMP after cSiO2 exposure. 
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Figure 5: HCQ does not affect uptake of cSiO2 in vitro.  
 
BMDM which have taken up cSiO2 into their phagolysosomes have higher side-scatter (SSC). 
BMDM exposed to cSiO2 ± HCQ had significantly higher side scatter (****p < 0.0001) than 
BMDM not exposed to cSiO2. There was no difference between the SSC of control vs HCQ-treated 
cells nor cSiO2 vs HCQ + cSiO2 cells; therefore, HCQ does not affect the ability of the BMDM to 
phagocytize cSiO2 particles. n = 3 
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Figure 6: HCQ reduces the uptake of LysoTracker in vitro.  
 
BMDM were treated with LysoTracker Red DND-99 at 50 nM for 30 min to assess the relative 
acidity of the lysosomes. HCQ treated cells showed less uptake of LysoTracker. Cells exposed to 
cSiO2 without HCQ treatment had significantly (*p < 0.05) more LysoTracker uptake than cells 
exposed to cSiO2 and treated with HCQ. n = 3 
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3.3 HCQ blocks LMP in vitro 
 
Direct quantification of the ability of HCQ to block LMP  in vitro was assessed through a method 
modified from Aits et al. which measures the release of β-N-acetyl-glucosaminidase (NAG) into 
the cytosol after cell permeabilization by the detergent digitonin (Aits et al., 2015). NAG is a 
lysosomal hydrolase which is not present in the cytosol unless the lysosomal membrane has been 
compromised. Using BMDM the level of digitonin is titrated so that the cell membrane is 
permeabilized while the lysosomal membrane remains intact. The lysosomal membrane contains 
less cholesterol than the cell membrane making the digitonin required to permeabilize the 
lysosomal membrane higher than that required for the cell membrane (Aits et al., 2015). BMDM 
were treated with or without HCQ (25 µM) and with or without cSiO2 (50 µg/mL) and incubated 
for 4 or 24 hours. Cytosolic LDH activity was measured as described above and used as a control 
to which the NAG activities were normalized. HCQ was able to significantly block the release of 
NAG from lysosomes after both 4 (*p < 0.05) and 24 (***p < 0.001) hours. This shows that HCQ 
blocks cSiO2-induced LMP in vitro. 
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Figure 7: HCQ blocks LMP in vitro. 
 
BMDM were treated with or without HCQ (25 µM) and with or without cSiO2 (50 µg/mL) and 
incubated for 4 or 24 hours. HCQ was able to significantly block the release of NAG from 
lysosomes after both 4 (*p < 0.05) and 24 (***p < 0.001) hour cSiO2 exposures. n = 3 
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3.4 Evaluation of HCQ on cSiO2 uptake in vivo 
 
 
The above in vitro studies demonstrated that HCQ accumulated in macrophages and blocked the 
ability of cSiO2 to cause LMP and downstream events including toxicity and NLRP3 
inflammasome activation as determined by IL-1b release. However, in vivo studies have not been 
previously conducted in order to determine whether the in vitro studies predict in vivo outcomes. 
Therefore, C57Bl/6 mice were treated with HCQ at 10 mg/kg/day or PBS by oral gavage for 7 
days. This dose of HCQ was chosen based on previous in vivo studies with HCQ (X. Chen et al., 
2017; Gómez-Guzmán et al., 2014). At the end of the 7-day pre-treatment period, mice were 
exposed to either 0.25 mg or 1 mg of cSiO2 by oropharyngeal instillation (in 50 µL of dispersion 
media). Control mice received only dispersion media. Mice were sacrificed 24 hours post cSiO2 
exposure. The 1 mg of cSiO2 exposure, has been commonly used in previous studies allowing 
comparison to previous results (Biswas et al., 2017). A lower dose of 0.25 mg was also evaluated. 
Naïve mice generally have around 3-4x105 AM residing in their lungs. Therefore, the 0.25 mg 
dosage more closely matches the in vitro dose used in this study of 50 µg/mL cSiO2 per 1x105 
BMDM. 
 
 In order to investigate whether HCQ was incorporated into the AM during the 7-day HCQ in vivo 
treatment, AM from whole lung lavage were treated with LysoTracker Red DND-99 and the cells 
analyzed by flow cytometry. As in the in vitro experiments, AM from mice treated with HCQ 
showed significantly less uptake of the LysoTracker dye. This finding suggests that in mice treated 
with HCQ at 10 mg/kg by oral gavage for 7 days did have HCQ sequestered into lysosomes of the 
AM (Fig. 8). Additionally, in order to rule out that HCQ was reducing toxicity due to changes in 
cSiO2 uptake by the AM in vivo, side scatter data of the whole lung lavage cells were collected by 
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flow cytometry. Side scatter was increased as expected in the cSiO2-treated mice and there was no 
difference between the control and HCQ-treated mice nor the cSiO2 and HCQ + cSiO2-treated 
mice. This matches the in vitro data showing that changes in cSiO2-induced toxicity in HCQ-
treated mice is not due to a change in the ability of the AM to phagocytize the cSiO2 (Fig. 9).    
 
 
 
Figure 8: HCQ accumulates in lysosomes of AM after treatment by oral gavage.  
 
AM from whole lung lavage of control or HCQ treated C57Bl/6 mice were incubated with 
LysoTracker Red DND-99 for 30 minutes prior to analysis by flow cytometry. In AM from mice 
treated with HCQ, there was significantly less uptake of the LysoTracker dye (*p < 0.05). This 
result is consistent with HCQ being sequestered into the lysosomes of the AM in vivo. n = 4 
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Figure 9: HCQ does not affect phagocytosis of cSiO2 by AM in vivo 
 
Whole lung lavage cells from mice treated in vivo ± HCQ and ± cSiO2.  Side scatter was increased 
as expected in the cSiO2-treated mice.  There was no difference between the control and HCQ-
treated mice nor the cSiO2 and HCQ + cSiO2-treated mice suggesting that a difference in the uptake 
of cSiO2 was not contributing to changes in toxicity. n = 4 
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3.5 Evaluation of HCQ on cSiO2-induced inflammation and toxicity in vivo 
 
Instillation of cSiO2 is known to cause lung inflammation and infiltration of immune cells. 
Therefore, differential cells counts were conducted on the whole lung lavage fluid (Fig. 10). At 
the 1 mg cSiO2 dose, there were no differences in the percentage of cells or the raw cell numbers 
between the HCQ treated mice and control mice ± cSiO2 exposure. Mice exposed to cSiO2 
displayed the expected neutrophilic infiltration. At the 0.25 mg cSiO2 dose, cSiO2-exposed mice 
which were treated with HCQ had a significant increase in the percentage of macrophages and a 
significant decrease in the percentage of neutrophils recruited to the lungs as compared to cSiO2 
exposed mice with no HCQ treatment. Additionally, cSiO2-exposed mice with HCQ treatment had 
a greater number of macrophages in their lungs 24 hours after cSiO2 exposure than did cSiO2 
exposed mice without HCQ treatment. This suggests that macrophages may be protected from 
cSiO2 induced pyroptosis with HCQ treatment.  
 
In order to evaluate lung injury following instillation of cSiO2, lavage supernatants were assayed 
for LDH release, total protein (bicinchoninic acid assay, BCA), relative total cathepsin, and 
relative cathepsin B levels (Fig. 11). Although not significant, LDH, total cathepsin, and cathepsin 
B release were all lower in HCQ treated mice at both the 0.25 mg and 1 mg cSiO2 exposures. Total 
area under the LDH curves for control and HCQ treated mice were 241.3 ± 100.6 and 165.1 ± 
52.58 respectively (Table 1). Surprisingly, LDH appeared to be higher in the 0.25 mg cSiO2 
exposed mice than the 1 mg cSiO2 exposed mice, relative to control mice. While data were 
normalized to control mice, the 0.25 mg cSiO2 exposure and the 1 mg cSiO2 experiments were 
conducted at different times and the LDH assays run on different days which could account for 
this apparent discrepancy. Total protein in the lung lavage supernatants, as measured by a BCA 
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assay, was used to assess lung injury. The BCA assay showed a slight decrease in the amount of 
protein in the lung lavage fluid at the 1 mg cSiO2 dose in HCQ-treated animals versus control. As 
expected the lung protein level increased as the cSiO2 dose increased in both control and HCQ-
treated mice.  
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Figure 10: HCQ-treated mice retain more AM and have less infiltration of neutrophils. 
 
Differential cell counts for 0.25 mg and 1 mg cSiO2 treated mice. At 1 mg of cSiO2, there were no 
differences in the percentage of cells or the raw cell numbers between the HCQ-treated mice and 
control mice ± cSiO2 exposure. Mice exposed to cSiO2 showed neutrophilic infiltration. At the 
0.25 mg cSiO2 dose, HCQ + cSiO2 mice had a significant increase in the percentage of 
macrophages (*p < 0.05) and a significant decrease in the percentage of neutrophils (**p < 0.01) 
as compared to cSiO2-exposed mice with no HCQ treatment. HCQ + cSiO2 mice had significantly 
more macrophages in their lungs 24 hours after cSiO2 exposure than did cSiO2-exposed mice 
without HCQ treatment (*p < 0.05).  n = 4-5 
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Figure 11: HCQ reduces cSiO2 toxicity in vivo 
 
LDH, total cathepsin, and cathepsin B release were lower in HCQ-treated mice at both 0.25 mg 
and 1 mg cSiO2 exposures. The BCA assay showed a slight decrease in the amount of protein in 
the lung lavage fluid at the 1 mg cSiO2 dose in HCQ-treated animals versus control. As expected 
the protein level increased as the cSiO2 dose increased in both control and HCQ-treated mice. 
 n = 4-5. 
 
Table 1: Total Area Under the Curve for LDH Release 
 
Total Area Under the Curve for LDH Release 
 Control HCQ Treated 
Total Area 241.3 ± 100.6 165.1 ± 52.58 
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3.6 In vivo cytokine production after HCQ treatment. 
 
Cytokines from lung lavage supernatants were measured by a multiplex immunoassay (MSD U-
PLEX, Meso Scale Diagnostics) because of the sensitivity and small sample size used (Figs. 12 
and 13). Seven cytokines IFN-g, IL-1b, IL-6, IL-10, IL-13, IL-33, and TNF-a were included in 
the 7-plex plate used for this experiment. IL-10 and IL-13 levels were below detection levels for 
both 0.25 mg and 1 mg cSiO2-exposures and were not graphed. For mice exposed to 1 mg of cSiO2, 
IFN-g was only detectable in the cSiO2 exposed group suggesting that HCQ was able to reduce 
IFN-g after cSiO2 exposure (*p < 0.05). While not significant, there was a trend that IL-6, IL-33, 
and TNF-a appeared to be lower with HCQ treatment in the 1 mg cSiO2 exposed mice.  IL-1b did 
not appear to be blocked with HCQ treatment. For the 0.25 mg dose, IFN-g again appeared to be 
decreased by HCQ treatment, although in this case it was not statistically significant due to a large 
variance in the cSiO2-exposed group. As in the 1 mg dose group, there is was a trend that HCQ + 
cSiO2 mice seem to have lower levels of TNF-a as compared to cSiO2 only mice. In all graphs, no 
visible bar signifies that levels were below detection. 
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Figure 12: Cytokines after 1 mg SiO2 exposure 
Cytokines from lung lavage supernatants measured by a multiplex immunoassay. IFN-g was only 
detectable in the cSiO2-exposed group suggesting that HCQ was able to block IFN-g after cSiO2 
exposure (*p < 0.05). While not significant, the data suggest a trend toward HCQ decreasing 
production of IL-6, IL-33, and TNF-a. IL-1b did not appear to be blocked with HCQ treatment.  
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Figure 13: Cytokines after 0.25 mg SiO2 exposure 
For the 0.25 mg dose, IFN-g appeared to be decreased by HCQ treatment, though not statistically 
significant due to a large variance in the cSiO2-exposed group. As in the 1 mg dose group, there is 
a trend that HCQ + cSiO2 mice seem to have lower levels of TNF-a as compared to cSiO2 only 
mice. n = 4-5 
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3.7 HCQ blocks IL-1b production in ex vivo culture 
 
Since HCQ was effective in blocking silica-induced IL-1b release from AM and the data showed 
that HCQ was taken up by lysosomes in AM, the AM from the mice were evaluated ex vivo. Cells 
collected during the whole lung lavage of mice treated with 0.25 mg of cSiO2 in vivo were plated 
for ex vivo IL-1b culture and primed with LPS. After incubation, supernatants were assayed for 
IL-1b by ELISA. Data were normalized to IL-1b release per 1x105 AM using the total cell count 
and percent of macrophages. Control and HCQ treated cells had very little IL-1b production as 
expected. Consistent with the in vitro data, cells from HCQ + cSiO2 treated mice had a significantly 
less IL-1b production when compared to cSiO2 exposed mice not treated with HCQ. These data 
are consistent with HCQ being able to prevent LMP after cSiO2 exposure in vivo.  
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Figure 14: Ex Vivo Culture of C57Bl/6 AM  
Cells collected during the whole lung lavage of mice treated with 0.25 mg of cSiO2 in vivo were 
plated for ex vivo IL-1b culture. Data were normalized to IL-1b release per 1x105 AM using the 
total cell count and percent of macrophages. Control and HCQ-treated cells produced only trace 
amounts of IL-1b. Cells from HCQ + cSiO2 treated mice had significantly less IL-1b production 
when compared to cells from mice only exposed to cSiO2 (*p < 0.05). These data are consistent 
with HCQ being able to prevent LMP after cSiO2 exposure in vivo. n = 4-6 
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Chapter 4: Discussion 
 
Silicosis is a progressive, fibrotic pulmonary disease that occurs after exposure to inhaled cSiO2. 
The loss of pulmonary function resulting from silicosis causes significant morbidity and, in severe 
cases, mortality. Treatment options are limited to supporting respiratory function through 
supplemental oxygen and decreasing inflammation with corticosteroids (Leung et al., 2012). A 
growing body of evidence suggests that a key step in cSiO2-induced lung inflammation is 
activation of the NLRP3 inflammasome resulting in the release of pleiotropic cytokines such as 
IL-1b and IL-18. At this time there is limited information on possible pharmaceutical approaches 
to regulation of NLRP3 inflammasome activity.  However, it may be possible to regulate LMP, 
which has been proposed to precede NLRP3 inflammasome activation (Sayan & Mossman, 2016; 
Serrano-Puebla & Boya, 2016). When cSiO2 is phagocytized by resident AM in an attempt to clear 
the particles from the lungs, the cSiO2 compromises lysosomal membranes allowing lysosomal 
proteases to leak into the cytosol and induce NLRP3 inflammasome assembly (P Boya & Kroemer, 
2008; Bunderson-Schelvan et al., 2016; Jessop et al., 2017). Therefore, blocking LMP would 
attenuate NLRP3 inflammasome assembly and could be a key mechanism to target in order to treat 
cSiO2-induced inflammation. HCQ was chosen for this research because it is cationic amphiphilic 
drug (CAD) that is known to accumulate in lysosomes (Ben-Zvi et al., 2012; Patricia Boya et al., 
2003). CADs diffuse through membranes in an unprotonated state but become protonated in the 
acidic environment of lysosomes, losing their ability to diffuse back out through lipid membranes. 
HCQ is used extensively as an anti-malarial and also to treat autoimmune diseases such as systemic 
lupus erythematosus (SLE). However, the precise mechanism to explain its action in SLE is 
unclear (Ben-Zvi et al., 2012). 
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The in vitro work from this study strongly supports the hypothesis that HCQ is able to block cSiO2-
induced LMP. HCQ was able to rescue BMDM from cell death after exposure to 50 or 100 µg/mL 
of cSiO2 (Fig. 3).  HCQ also caused significant reduction in the production of IL-1β in BMDM 
after cSiO2 exposure (Fig. 4). These data are consistent with a 2017 paper by Chen et al. where 
they found that chloroquine (which differs from HCQ by one hydroxyl group) suppresses NLRP3 
inflammasome activation in a murine model of endotoxic shock (X. Chen et al., 2017). Chen et al. 
showed that chloroquine is able to decrease IL-1β and IL-18 release from BMDM stimulated with 
LPS. They also found that chloroquine inhibits transcription of Nlrp3 genes. Their research, 
however, did not examine the effect of HCQ on cSiO2-induced toxicity.  
 
Our research also directly measured the ability of HCQ to prevent LMP by measuring the release 
of β-N-acetyl-glucosaminidase (NAG) into the cytosol. HCQ was able to block NAG release in 
BMDM exposed to cSiO2 at both 4 and 24 hours (Fig. 5). This data conflicts with data published 
by Boya et al. in 2003 where they argue that HCQ induces LMP.  When cells were stained by 
immunofluorescence for cathepsin B, they saw that HCQ caused cathepsin B staining to change 
from being contained in lysosomes to being diffuse throughout the cell. They also concluded that 
HCQ causes mitochondrial membrane permeabilization and apoptosis.  Boya et al. conducted their 
research in HeLa cells and also used some concentrations of HCQ which were higher than the 
concentrations used in this study (up to 60 µg/ml). They also did not measure LMP through a 
digitonin lysosomal permeability assay measuring NAG, but instead used microscopy to determine 
if LMP was occurring; therefore, it is hard to make direct comparisons between their research and 
the research presented in this paper (Patricia Boya et al., 2003). 
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The above in vitro results were predicated on the assumption that HCQ was being taken up into 
lysosomes. In order to test whether HCQ was becoming sequestered into the lysosomes, BMDM 
and AM were treated with LysoTracker. HCQ treatment reduced the amount of LysoTracker in 
lysosomes of both BMDM in vitro and AM in vivo.  These results are consistent with HCQ 
sequestration into the lysosomes of these cells.  The most likely mechanism by which HCQ is 
preventing the uptake of LysoTracker is due to HCQ increasing the pH of the lysosomes. 
Additionally, flow cytometry side scatter data from in vitro and in vivo experiments also confirmed 
that HCQ was not affecting the ability of cells to phagocytize the cSiO2 particles; therefore, the 
toxicity results were not due to changes in cell interactions with particles.   
 
Mice treated with HCQ in vivo showed modest reductions in cSiO2-induced toxicity. Overall, 
LDH, total cathepsins, cathepsin B, IFN-g and TNF-a trended lower in HCQ treated mice (Fig. 
11-13). It was surprising that cSiO2-induced increase in IL-1b in lung lavage fluid was not blocked 
in vivo by HCQ treatment; however, ex vivo culture of the AM from these same studies did result 
in significantly less IL-1b release in mice treated with HCQ. Several factors could have been 
responsible for the fact that there was not as pronounced of an effect in vivo as there was in vitro. 
It is possible that the dosing strategy and exposure time were not sufficient. Additionally, twenty-
four hours may be too short of a time to see differences in the immune response. While these 
results could indicate that the dose of HCQ was simply too low, the ex vivo results suggest that 
there was enough HCQ sequestered into the lysosomes to block inflammasome formation and IL-
1b production. The results from the ex vivo experiment may be explained by two differences: 1) 
the AM were primed for inflammasome activation with LPS when they were plated and 2) they 
were incubated for 24 hours in culture after isolation following in vivo cSiO2 exposure. LPS 
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stimulates the NF-𝜅B pathway increasing formation of the pro-form of IL-1b and increases the 
expression of NLRP3 inflammasome proteins (Sayan & Mossman, 2016). Therefore, it could be 
proposed that HCQ blocked IL-1b release by acting on the NF-kB pathway as previously proposed 
(X. Chen et al., 2017). In their studies, they pre-treated BMDM with chloroquine before adding 
LPS and saw a reduction of phospho-NF-𝜅B p65 protein levels in chloroquine-treated cells. 
However, in the in vitro experiments in this study LPS was added prior to HCQ treatment thereby 
allowing activation of the NF-kB pathway by LPS to proceed prior to any potential inhibition by 
HCQ.  Since, there was still a reduction in IL-1b production, it supports the notion that the action 
of HCQ to block IL-1b is not at NF-kB but rather at blocking LMP.  
 
Previous research from our laboratory has shown that the tricyclic antidepressant, imipramine, was 
able to decrease cSiO2-induced toxicity in vitro and in vivo (Biswas et al., 2017). Because HCQ 
and IMP are both lysosomotropic drugs that sequester in lysosomes, we hypothesized that they 
would have a similar ability to protect lysosomes from cSiO2-induced LMP. The imipramine study 
showed similar results as HCQ in the ability to prevent IL-1β production in vitro and in an ex vivo 
culture.  IMP was also able to decrease IL-1b levels in the lavage fluid in vivo after a 24-hour 
cSiO2 exposure, which was not seen with HCQ.  In long-term exposure studies, IMP-treated mice 
had less lung pathology and hydroxyproline levels. It is unknown whether other CADs may have 
similar protective effects on lysosomal membrane stability after particle exposure and further work 
should be done to better understand the interactions between CAD and cSiO2 exposure. To our 
knowledge, no other work has been done linking a pharmaceutical intervention with the ability to 
block cSiO2-induced LMP.   
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Chapter 5: Conclusions and Further Directions 
 
The results of this study support the hypothesis that HCQ can prevent lysosomal membrane 
permeability from exposure to cSiO2. The in vitro data strongly suggests that HCQ attenuates 
activation of the NLRP3 inflammasome and is doing this, at least in part, by blocking LMP. Cell 
death after cSiO2 exposure was decreased with HCQ treatment in vitro. HCQ was able to block the 
production of IL-1β and the release of NAG into the cytosol in cSiO2-exposed BMDM indicating 
that LMP was being prevented. This was the first study to show that HCQ is able to block LMP. 
While the in vivo data is less definitive, it also indicates that HCQ may be protective against cSiO2 
toxicity in vivo. These studies were able to confirm that HCQ is accumulating in lysosomes of AM 
when mice are treated with HCQ by gavage for 7 days. Data also indicated that HCQ was not 
affecting AM’s ability to phagocytize cSiO2 particles. LDH, total cathepsins, and cathepsin B, IFN-
g, and TNF-a levels trended lower in HCQ-treated mice. Increasing the power of the study by 
including more mice would improve the reproducibility of the studies and clarify these differences. 
It was surprising that the increase in cSiO2-induced increase of IL-1b in the lung lavage fluid was 
not blocked in vivo by HCQ treatment; however, ex vivo culture of the AM did result in 
significantly less IL-1b release in mice that were treated with HCQ.  
 
This study was limited by the short time-frame for the in vivo studies. Mice in this study were 
sacrificed 24 hours after cSiO2 exposure in order to assess the acute inflammatory response; 
however, this time frame is too short to observe histological changes in the lungs. Future studies 
would benefit from longer-term exposures to discern if HCQ is able to block the development of 
fibrosis and cSiO2-induced pulmonary pathology. Additionally, the dosage and treatment 
schedules were determined based on previous literature; however, in order to see more profound 
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effects from HCQ, it could be beneficial to increase the dose or lengthen the treatment period (X. 
Chen et al., 2017; Gómez-Guzmán et al., 2014). Additionally, this study only assessed the ability 
of HCQ to block cSiO2 toxicity by pre-treating cells or mice with HCQ before exposure to cSiO2. 
While it is beneficial to have options for prophylactic treatment for individuals who know they 
will be exposed to cSiO2, such as military personnel deployed to arid regions, most treatments for 
cSiO2 inhalation occur after an exposure has occurred. Therefore, it would be important to conduct 
further studies that examine the ability of HCQ to block cSiO2-induced lung injury after exposure.  
 
A large number of workers are exposed to airborne cSiO2 which can contribute to the development 
of pulmonary and systemic disease. It is increasingly being recognized that lysosomes are 
important modulators of disease; however, there are virtually no pharmaceuticals directed at a 
lysosomal mechanism of disease. Many pharmaceuticals become sequestered in the lysosome 
through an ion-trapping mechanism, yet this has been considered an undesirable side-effect of the 
drugs. The data in this study show HCQ can prevent LMP induced by cSiO2 by accumulating in 
lysosomes.  It is unknown if other CAD have similar effects on lysosomal membrane stability, and 
examining the ways that these drugs interact with lysosomal membranes may provide insight into 
their ability to be used as treatments for inhaled particle exposures. Further work should be done 
to elucidate the how pharmaceuticals affecting lysosomes may be used to treat diseases caused by 
inhaled particles. 
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